Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine

Ketamine

Brief Summary

The purpose of this project is to test how ketamine, an analgesics currently employed in the pre-hospital setting by the US Army, alters the capacity to tolerate a hemorrhagic insult in humans.

Intervention / Treatment

  • Ketamine Hydrochloride (DRUG)
    A total of 20 mg of Ketamine Hydrochloride will be administered intravenously
  • Placebo (OTHER)
    Subjects will receive placebo

Condition or Disease

  • Hemorrhage
  • Healthy

Phase

  • Phase 4

    • Study Design

    Study type: INTERVENTIONAL
    Status: Completed
    Study results: No Results Available
    Age: 18 Years to 45 Years
    Enrollment: 43 (ACTUAL)
    Funded by: Other|U.S. Fed
    Allocation: Randomized
    Primary Purpose: Supportive Care

    Masking

    DOUBLE:
    • Participant
    • Outcomes Assessor

    Clinical Trial Dates

    Start date: Jun 01, 2018 ACTUAL
    Primary Completion: Jun 30, 2021 ACTUAL
    Completion Date: Jun 30, 2021 ACTUAL
    Study First Posted: Aug 08, 2018 ACTUAL
    Results First Posted: Nov 26, 2021 ACTUAL
    Last Updated: Oct 29, 2021

    Sponsors / Collaborators

    Lead Sponsor: University of Texas Southwestern Medical Center
    Responsible Party: N/A

    Location

    Dallas, Texas, USA

    Pain management on the battlefield is critical for the wellbeing of the soldier. Given that a hemorrhagic injury on the battlefield is virtually always associated with pain, it is paramount that the selected pain medication does not disrupt appropriate physiological mechanisms that are beneficial towards the maintenance of blood pressure and vital organ blood flow during that hemorrhagic insult. Current guidelines for the selection of pain medications of a hemorrhaging soldier are based upon limited scientific evidence, with the vast majority of supporting studies being conducted on anesthetized animals. Thus, the interaction between hemorrhagic shock and pain medications commonly employed on the battlefield is yet to be determined in the conscious humans.

    With this background, we will test the hypothesis that ketamine will impair the capacity for a conscious human to tolerate a hemorrhagic insult.

    The obtained data will provide the necessary scientific evidence in humans to support the Committee on Tactical Combat Casualty Care (CoTCCC) guidelines on the analgesic of choice for moderate to severe injuries where the casualty is in hemorrhagic shock. Notably, such data will identify the analgesic that least compromises a human's ability to tolerate a hemorrhagic insult, ultimately providing critical information to the combat medic on which analgesic should be employed for such an injury.

    Participant Groups

    • Subjects will receive up to 20 mg Ketamine Hydrochloride while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.

    • Subjects will receive placebo while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.

    Eligibility Criteria

    Sex: All
    Minimum Age: 18
    Maximum Age: 45
    Age Groups: Adult
    Healthy Volunteers: Yes

    Inclusion Criteria:

    * 18-45 years of age
    * Healthy
    * Non-obese (body mass index less than 30 kg/m2)
    * Body mass greater than or equal to 65 kg

    Exclusion Criteria:

    * Subjects not in the defined age range
    * Subjects who have cardiac, respiratory, neurological and/or metabolic illnesses
    * Any known history of renal or hepatic insufficiency/disease
    * Pregnancy or breast feeding
    * Body mass less than 65 kg
    * Current smokers, as well as individuals who regularly smoked within the past 3 years
    * Positive urine drug screen
    * Currently taking pain modifying medication(s)

    Primary Outcomes

    • Tolerance to a simulated hemorrhagic challenge will be assessed, for both the placebo and ketamine limbs, by causing progressive central hypovolemia via lower-body negative pressure (LBNP). This progressive lower-body negative pressure challenge will be performed until the onset of syncopal symptoms (defined as: profound bradycardia, a precipitous drop in arterial blood pressure and accompanying narrowing of pulse pressure, a sustained systolic blood pressure less than 80 mmHg, and/or subjective symptoms such as light-headedness, sweating, nausea, or dizziness). The primary variable will be the quantification of lower-body negative pressure that is required to cause these symptoms. This quantification will be objectively measured via a cumulative stress index which is calculated as the sum of the product of the LBNP level and the duration of each level, until test termination (i.e., 40 mmHg x 3 min + 50 mmHg x 3 min, etc).

    Secondary Outcomes

    • Pain assessments will be conducted using a digital algometer to obtain maximum pain thresholds caused by pressure. This pain assessment technique is conducted by applying the tip of a hand-held digital algometer on the subject's digit. Force is gradually increased and the peak force is recorded when the subject first reports a painful sensation. Removal of the pressure from the algometer immediately relieves the painful sensation and the subject can voluntarily stop the test at any time. This assessment will be performed after the subject has received placebo and ketamine.

    More Details

    NCT Number: NCT03621085
    Other IDs: STU 092017-068
    Study URL: https://clinicaltrials.gov/study/NCT03621085
    Last updated: Sep 29, 2023